Operator

Good afternoon, ladies and gentlemen, and welcome to the Cytosorbents' First Quarter 2026 Earnings Conference Call.

[Operator Instructions]

As a reminder, this call is being recorded.

And now I would like to turn the conference over to Pete Mariani, Chief Financial Officer. Please go ahead.

Peter Mariani
Chief Financial Officer

Thank you, Kathleen, and good afternoon, everyone. Welcome to Cytosorbents' First Quarter 2026 Conference Call.

Joining me today is Dr. Phil Chan, our Chief Executive Officer; and Dr. Makis Deliargyris, our Chief Medical Officer.

Before I turn the call over to Phil, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements, which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions. Therefore, the company claims protection under the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today. The forward-looking statements may make -- we make reflect our views and estimates as of today, May 13, 2026, and we assume no obligation to update these projections in the future as market conditions change.

We encourage investors to review the risks discussed in our annual report on Form 10-K filed with the SEC on March 30, 2026. And as updated by the risks reported in our quarterly reports on Form 10-Q and in press releases and other communications to shareholders issued from time to time.